Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

Reynald Castañeda

Deputy Editor

MADRID — Amgen’s Phase II trial of its bispecific T cell engager tarlatamab showed a response rate of 40% of patients with small cell lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

The key to faster, more impactful research? Put patients in the driver’s seat

Up­dat­ed: Am­gen spot­lights new ef­fi­ca­cy, safe­ty da­ta of mid-phase tar­latam­ab tri­al in hard-to-treat can­cer: #ES­MO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

The key to faster, more impactful research? Put patients in the driver’s seat